wodroulette| Heavy Pharmaceutical Holdings has ranked among the top five in the industry for four consecutive years. Last year, revenue exceeded 80 billion yuan, a year-on-year increase of more than 18%

Newsletter summary

[heavy Pharmaceutical Holdings ranks among the top five in the industry for four consecutive years. Last year, revenue exceeded 80 billion yuan, an increase of more than 18% over the same period last year.] Securities TimesWodroulette, May 14WodrouletteUnder the guidance of the Department of Market Operation and Consumer Promotion of the Ministry of Commerce, sponsored by China Pharmaceutical Business Association, Guoyao Lizhan Exhibition Co., Ltd., China Pharmaceutical CommerceWodroulette.Wodroulette..

Text of news flash

[heavy Pharmaceutical Holdings ranks among the top five in the industry for four consecutive years. Last year, revenue exceeded 80 billion yuan compared with the same period last year.] Securities Times net News, May 14, under the guidance of the Department of Market Operation and Consumer Promotion of the Ministry of Commerce, sponsored by China Pharmaceutical Business Association and Guoyao Lizhan Exhibition Co., Ltd. The China Pharmaceutical Circulation Industry supply-side structural Reform and Innovation Forum (Q8), co-organized by the device Circulation Branch of China Pharmaceutical Business Association and the ESG Branch of China Pharmaceutical Business Association, opened in Shanghai and released the Top 20 list of main business income of wholesale enterprises in China's pharmaceutical circulation industry in 2023. Heavy Pharmaceutical Holdings (000950) ranked fifth in the main business income of wholesale enterprises in China's pharmaceutical circulation industry in 2023, ranking among the top five in the country's pharmaceutical business for four consecutive years. In 2023, centering on the "14th five-year Plan" strategic guiding ideology of "1200 double three hundred cities and Sanhua SiNeng Fifth Route Army", heavy Pharmaceutical Holdings persisted in making progress in the midst of stability, achieving a business income of 80.119 billion yuan, an increase of 18.12% over the same period last year. The company has completed nearly 20 equity investment projects through newly established or external mergers and acquisitions, bringing incremental sales of nearly 2.5 billion yuan, filling many blank markets such as Heilongjiang, Hebei and Guangxi, and the commercial network covers 32 provinces, autonomous regions and cities. To achieve the full layout of provincial platforms except Macao and Taiwan, and gradually achieve the goal of layout in more than 300 prefecture-level cities across the country, the annual sales income of more than 1000 retail stores exceeds 3 billion yuan. At the same time, with optimizing the industrial structure and speeding up innovation and upgrading as the main line, we continue to explore the layout of new business sectors such as medical beauty, veterinary drugs and specialty food, and successfully open up new business in nuclear drugs. In addition, heavy Pharmaceutical Holdings insists on taking "business digitization" as a key content of the "14th five-year Plan" strategy, based on the needs of enterprise strategic development, integrates the latest digital technology, reconstructs and upgrades the top-level architecture of IT, synchronously promotes the construction of technology, business and data platforms, builds the group's digital base, builds a digital capability platform, and empowers various sectors of business application and management to meet the rapid response requirements of business innovation. Help Power Group to upgrade from the traditional distribution commercial enterprises to the high-quality development of "Internet + Medicine" integrated modern pharmaceutical business. Since the launch of pharmaceutical research and development in 2017, heavy Pharmaceutical Holdings has persisted in giving priority to high-end generic drugs and actively developed varieties of characteristic traditional Chinese medicine, with more than 10 projects under research, involving cardio-cerebrovascular, mental nerves, digestion and metabolism, autoimmunity and other therapeutic fields. at present, olmesartan axetil tablets have been commercialized. Two MAH varieties, Preba capsule and Topatibu Citrate tablets, have obtained the Drug Registration Certificate approved and issued by the State Drug Administration. The other varieties are in different stages of pharmacy, clinical and registration application, and the echelon has been formed in the research project. (Zheng Yuchuan) proofread: Yao Yuan